243 related articles for article (PubMed ID: 27084804)
1. Serial galectin-3 and future cardiovascular disease in the general population.
van der Velde AR; Meijers WC; Ho JE; Brouwers FP; Rienstra M; Bakker SJ; Muller Kobold AC; van Veldhuisen DJ; van Gilst WH; van der Harst P; de Boer RA
Heart; 2016 Jul; 102(14):1134-41. PubMed ID: 27084804
[TBL] [Abstract][Full Text] [Related]
2. The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure.
Zhang Y; Zhang R; An T; Huang Y; Guo X; Yin S; Wang Y; Ji S; Lv R; Zhang J; Maisel A
J Card Fail; 2015 Jan; 21(1):51-9. PubMed ID: 25463412
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.
van der Velde AR; Gullestad L; Ueland T; Aukrust P; Guo Y; Adourian A; Muntendam P; van Veldhuisen DJ; de Boer RA
Circ Heart Fail; 2013 Mar; 6(2):219-26. PubMed ID: 23395934
[TBL] [Abstract][Full Text] [Related]
4. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Motiwala SR; Szymonifka J; Belcher A; Weiner RB; Baggish AL; Sluss P; Gaggin HK; Bhardwaj A; Januzzi JL
Eur J Heart Fail; 2013 Oct; 15(10):1157-63. PubMed ID: 23666680
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure.
van Vark LC; Lesman-Leegte I; Baart SJ; Postmus D; Pinto YM; de Boer RA; Asselbergs FW; Wajon EMCJ; Orsel JG; Boersma E; Hillege HL; Akkerhuis KM;
J Am Heart Assoc; 2017 Nov; 6(12):. PubMed ID: 29187387
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of galectin-3 on admission in Chinese patients with heart failure: a prospective observational study.
Wang H; Chen Q; Li Y; Jing X; Liang T; Yang J
Acta Cardiol; 2017 Apr; 72(2):188-195. PubMed ID: 28597803
[TBL] [Abstract][Full Text] [Related]
8. The fibrosis marker galectin-3 and outcome in the general population.
de Boer RA; van Veldhuisen DJ; Gansevoort RT; Muller Kobold AC; van Gilst WH; Hillege HL; Bakker SJ; van der Harst P
J Intern Med; 2012 Jul; 272(1):55-64. PubMed ID: 22026577
[TBL] [Abstract][Full Text] [Related]
9. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
[TBL] [Abstract][Full Text] [Related]
10. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.
Ho JE; Liu C; Lyass A; Courchesne P; Pencina MJ; Vasan RS; Larson MG; Levy D
J Am Coll Cardiol; 2012 Oct; 60(14):1249-56. PubMed ID: 22939561
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
Lok DJ; Van Der Meer P; de la Porte PW; Lipsic E; Van Wijngaarden J; Hillege HL; van Veldhuisen DJ
Clin Res Cardiol; 2010 May; 99(5):323-8. PubMed ID: 20130888
[TBL] [Abstract][Full Text] [Related]
13. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials.
Meijers WC; Januzzi JL; deFilippi C; Adourian AS; Shah SJ; van Veldhuisen DJ; de Boer RA
Am Heart J; 2014 Jun; 167(6):853-60.e4. PubMed ID: 24890535
[TBL] [Abstract][Full Text] [Related]
14. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty.
Szadkowska I; Wlazeł RN; Migała M; Szadkowski K; Zielińska M; Paradowski M; Pawlicki L
Cardiol J; 2013; 20(6):577-82. PubMed ID: 24338533
[TBL] [Abstract][Full Text] [Related]
15. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.
Wang CH; Yang NI; Liu MH; Hsu KH; Kuo LT
Cardiol J; 2016; 23(5):563-572. PubMed ID: 27515479
[TBL] [Abstract][Full Text] [Related]
16. Impact of diabetes on the predictive value of heart failure biomarkers.
Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A
Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845
[TBL] [Abstract][Full Text] [Related]
17. Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.
Coromilas E; Que-Xu EC; Moore D; Kato TS; Wu C; Ji R; Givens R; Jorde UP; Takayama H; Naka Y; George I; Mancini D; Schulze PC
BMC Cardiovasc Disord; 2016 Jun; 16():138. PubMed ID: 27301475
[TBL] [Abstract][Full Text] [Related]
18. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population.
Imran TF; Shin HJ; Mathenge N; Wang F; Kim B; Joseph J; Gaziano JM; Djoussé L
Am J Cardiol; 2017 Jan; 119(1):57-64. PubMed ID: 28247849
[TBL] [Abstract][Full Text] [Related]
19. Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
Stolen CM; Adourian A; Meyer TE; Stein KM; Solomon SD
J Card Fail; 2014 Nov; 20(11):793-9. PubMed ID: 25106783
[TBL] [Abstract][Full Text] [Related]
20. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
van Kimmenade RR; Januzzi JL; Ellinor PT; Sharma UC; Bakker JA; Low AF; Martinez A; Crijns HJ; MacRae CA; Menheere PP; Pinto YM
J Am Coll Cardiol; 2006 Sep; 48(6):1217-24. PubMed ID: 16979009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
